Related Experiment Videos
An EP2 receptor-selective prostaglandin E2 agonist induces bone healing
V M Paralkar1, F Borovecki, H Z Ke
1Pfizer Global Research and Development, Groton Laboratories, CT 06340, USA. vishwas_m_paralkar@groton.pfizer.com
Summary
Researchers identified a novel compound, CP-533,536, that effectively promotes fracture healing. This EP2 receptor agonist offers a promising therapeutic alternative for bone repair without Prostaglandin E2 (PGE2) side effects.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Orthopedic Research
Background:
- Impaired fracture healing leads to significant morbidity and mortality.
- Prostaglandin E2 (PGE2) enhances bone mass and strength but has unacceptable side effects.
- PGE2 exerts effects via EP1, EP2, EP3, and EP4 receptor subtypes.
Purpose of the Study:
- To identify a nonpeptidyl molecule for promoting fracture healing and preventing malunions.
- To investigate the role of EP2 and/or EP4 receptors in bone formation.
- To find a safer alternative to PGE2 for fracture treatment.
Main Methods:
- Screening for small molecules targeting Prostaglandin E2 (PGE2) pathways.
- Utilizing a canine long bone segmental defect and fracture model.
- Evaluating the efficacy and side effect profile of candidate molecules.
Main Results:
- Identified CP-533,536, a selective EP2 receptor agonist.
- CP-533,536 demonstrated effective healing in canine fracture models.
- The compound did not produce the adverse side effects associated with PGE2.
Conclusions:
- The EP2 receptor is a key mediator of Prostaglandin E2's (PGE2) bone-building activity.
- CP-533,536 represents a potent therapeutic agent for bone defect and fracture treatment.
- Targeting the EP2 receptor offers a viable strategy for enhancing fracture healing.